Edition:
United Kingdom

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

34.76USD
14 Nov 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$34.76
Open
$37.00
Day's High
$37.32
Day's Low
$33.70
Volume
662,538
Avg. Vol
278,502
52-wk High
$73.90
52-wk Low
$16.71

Chart for

About

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct... (more)

Overall

Beta: --
Market Cap(Mil.): $783.42
Shares Outstanding(Mil.): 40.59
Dividend: --
Yield (%): --

Financials

  CRSP.OQ Industry Sector
P/E (TTM): -- 85.49 33.64
EPS (TTM): -0.07 -- --
ROI: -16.50 -0.29 14.22
ROE: -56.05 0.40 15.99

CRISPR gene editing can cause risky collateral DNA damage: study

LONDON Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

16 Jul 2018

UPDATE 2-CRISPR gene editing can cause risky collateral DNA damage - study

LONDON, July 16 Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

16 Jul 2018

Earnings vs. Estimates